Document Detail

Prophylactic intracameral cefuroxime. Evaluation of safety and kinetics in cataract surgery.
MedLine Citation:
PMID:  12036640     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the safety and kinetics of prophylactic intracameral cefuroxime in cataract surgery. SETTING: Department of Ophthalmology, St. Eriks Hospital, Stockholm, Sweden. METHODS: In a nonrandomized observer-masked best-case trial, the visual rehabilitation and the evolution of laser flare intensity and corneal endothelial cell density after cataract surgery were assessed in 45 patients receiving intracameral cefuroxime and in 45 control patients. Immunoglobulin E-mediated sensitivity was evaluated using a skin prick test to cefuroxime in a screening program comprising all cataract patients operated on in 1997. Intracameral concentrations of cefuroxime in samples retrieved 30 seconds (n = 10) and 1 hour (n = 9) postoperatively were evaluated in an observer-masked fashion with a microbiological assay. RESULTS: Intracameral cefuroxime did not have a statistically significant effect on postoperative visual acuity, induced laser flare intensity, or endothelial cell loss compared with nonadministration of intracameral antibiotic prophylaxis. Three positive skin prick tests to cefuroxime were found in the 5813 screened cataract patients. The median aqueous humor concentration of cefuroxime at 30 seconds was 2742 mg/L, declining to 756 mg/L 1 hour after drug instillation. CONCLUSIONS: Intracameral cefuroxime 1 mg appears safe in terms of local toxicity. Immunoglobulin E-mediated allergy to cefuroxime is rare in the cataract population. The treatment achieved high aqueous concentrations even 1 hour after surgery.
Per G Montan; Gisela Wejde; Hans Setterquist; Margareta Rylander; Charlotta Zetterström
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cataract and refractive surgery     Volume:  28     ISSN:  0886-3350     ISO Abbreviation:  J Cataract Refract Surg     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-05-30     Completed Date:  2002-07-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8604171     Medline TA:  J Cataract Refract Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  982-7     Citation Subset:  IM    
Department of Ophthalmology, St. Eriks Hospital Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibiotic Prophylaxis*
Aqueous Humor / drug effects,  metabolism*
Cefuroxime / pharmacokinetics*,  therapeutic use
Cell Count
Cephalosporins / pharmacokinetics*,  therapeutic use
Double-Blind Method
Drug Evaluation
Drug Hypersensitivity / metabolism
Endophthalmitis / metabolism,  microbiology,  prevention & control
Endothelium, Corneal / cytology,  drug effects
Eye Infections, Bacterial / etiology,  metabolism,  prevention & control
Visual Acuity / drug effects
Reg. No./Substance:
0/Cephalosporins; 55268-75-2/Cefuroxime

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prophylactic intracameral cefuroxime. Efficacy in preventing endophthalmitis after cataract surgery.
Next Document:  Determining the lowest trypan blue concentration that satisfactorily stains the anterior capsule.